Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Nov;56(5):513-9.
doi: 10.1046/j.1365-2125.2003.01932.x.

The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension

D Patterson  1 , J Webster, G McInnes, A Brady, T MacDonald
Affiliations
Clinical Trial

The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension

D Patterson et al. Br J Clin Pharmacol. 2003 Nov.

Abstract

Aims: To compare the antihypertensive effect, and tolerability and safety of once daily doses of KT3-671 with that of placebo in patients with mild to moderate uncomplicated essential hypertension.

Methods: A randomised, multicentre, double blind, parallel-group comparison of KT3-671 with placebo. Hypertensive patients [Ambulatory Blood Pressure Monitoring (ABPM), mean daytime DBP > 90 mmHg, Office sitting mean DBP 95-114 after a 7-28 day washout period] entered a 2-week, single blind, run-in phase. Patients eligible for the double-blind phase were randomised to receive KT3-671 40 mg, 80 mg, 160 mg or placebo once daily over 4 weeks. The primary end-point was trough mean sitting office DBP. The study had 90% power to detect a 5 mmHg change between treatments and placebo at the 5% level of significance. The secondary end-points were 24 hour, daytime and night time mean ABPM.

Results: Office DBP was significantly lower with KT3-671 40 mg but not the other 2 dosage groups (-3.2; 95% CL -6.1 : -0.3 P < 0.03). Office SBP was significantly reduced with all dosage groups (40 mg -5.9, 95% CL -11 : -0.9; 80 mg -4.9, 95% CL -9.9 : 0.1 and 160 mg -5.7, 95% CL -10.8 : -0.7 P < 0.05). All doses of KT3-671 reduced systolic and diastolic ABPM. The number of patients with treatment related adverse events were comparable to placebo (38.8% KT3-671 vs 32.8% placebo). There was some evidence of a dose-response relationship with fall in nocturnal ABPM.

Conclusions: Oral KT3-671 was well tolerated. KT3-671 reduced office systolic BP at all doses and diastolic BP at some of the doses. Due to greater precision and power, the falls in mean ambulatory systolic and diastolic pressure were all significantly lower than placebo.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Satake N, Imanishi M, Keto Y, et al. The inhibitory effect of KT3-671, a nonpeptide angiotensin-receptor antagonist, on rabbit and rat isolated vascular smooth muscles: a possible involvement of K (ATP) channels. J Cardiovasc Pharmacol. 2000;35:457–467. - PubMed
    1. Takata Y, Kurihara J, Yoda T, et al. KT3-671, an angiotensin AT1 receptor antagonist, attenuates vascular but not cardiac responses to sympathetic nerve stimulation in pithed rats. J Cardiovasc Pharmacol. 2001;37:427–436. - PubMed
    1. Takata Y, Tajima S, Kato H. Inhibitory effect of KT3-671, a non-peptide angiotensin subtype 1 receptor antagonist, on sympathetic neurotransmission in isolated rabbit aorta. Pharmacol Res. 2000;41:335–340. - PubMed
    1. Takata Y, Tajima S, Mochizuki S, et al. Antihypertensive activity and pharmacokinetics of KD3-671, a nonpeptide AT1-receptor antagonist, in renal hypertensive dogs. J Cardiovasc Pharmacol. 1998;32:834–844. - PubMed
    1. Mochizuki S, Sato T, Furuta K, et al. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol. 1995;25:22–29. - PubMed

Publication types